Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00GFV
|
|||
| Former ID |
DIB004979
|
|||
| Drug Name |
Leridistim
|
|||
| Synonyms |
MPO, Searle; MPO-1; SC-70935; Myelopoietin (1), Searle
Click to Show/Hide
|
|||
| Indication | Immune System disease [ICD-11: 4A01-4B41; ICD-10: D80-D89] | Phase 2 | [1] | |
| Company |
GD Searle & Co
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 3 receptor (CSF2RB) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| PI3K-Akt signaling pathway | ||||
| Apoptosis | ||||
| Reactome | GPVI-mediated activation cascade | |||
| G beta:gamma signalling through PI3Kgamma | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| RAF/MAP kinase cascade | ||||
| Surfactant metabolism | ||||
| Interleukin receptor SHC signaling | ||||
| WikiPathways | IL-3 Signaling Pathway | |||
| Interleukin-2 signaling | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00004215) Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells. 2001;19(6):522-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.